Status: Not yet recruiting
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as measured by progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR).
Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Daiichi SankyoUpdated: Sep 1, 2026
Eligibility criteria
Adult participants with assigned female sex at birth. [+11]
Non-serous or non-endometrioid high-grade epithelial histology, or non-epithelia... [+45]